This medication is used to treat lung cancer. Osimertinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of osimertinib tablet brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the osimertinib tablet medicine cost price in India.
The order for osimertinib tablet will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
TAGRISSO™ (osimertinib) tablet, for oral use Initial U.S. Approval: 2015
Generic Name: osimertinib
Tablets: 80 mg and 40 mg.
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Osimertinib tablet on prescription and Import License in Patient's Name only.
For overseas patients, Osimertinib tablet can be made available in Send your enquiry to find Osimertinib tablet in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For TAGRISSO (osimertinib) tablet Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
AstraZeneca and Merck Get a Boost as FDA Approves New Use for Cancer Drug For More Details
Wakelee Discusses Debate Surrounding Osimertinib in Frontline EGFR-Mutant Lung Cancer.
Dated: Sunday, Mar 11, 2018